Product Information
ROFLUMILAST 250 MCG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $1.9069 per EA under NDC 68382062431. Its NADAC has been published 116 times since Apr 10, 2024.
Strength
250 ug/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382062431
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
ROFLUMILASTApproval Type
Generic (ANDA)
FDA Application
ANDA208303On Market Since
5/18/2023
Pharmacological Classes
Price Statistics
The NADAC for ROFLUMILAST 250 MCG TABLET has been published 116 times since Apr 10, 2024, and over the history we have for it it has declined 36.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9069 per EA |
|---|---|
| All-time high | $3.0148 (Apr 10, 2024) |
| All-time low | $1.5913 (Jul 17, 2024) |
| 52-week high | $2.4855 |
| 52-week low | $1.9069 |
| Median price | $2.3360 |
| Average price | $2.3187 |
| Largest weekly change | +63.4% (Aug 21, 2024) |
| Weeks tracked | 116 |
| Tracking since | Apr 10, 2024 |
Generic Alternatives
The matcher finds 5 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 5 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of ROFLUMILAST 250 MCG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ROFLUMILAST 250 MCG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $1.9069 per EA (NDC 68382062431), effective Jun 24, 2026.
How has the price of ROFLUMILAST 250 MCG TABLET changed over time?
Over the history we have for it, the NADAC for ROFLUMILAST 250 MCG TABLET has declined 36.7%. It has been tracked across 116 weekly CMS publications since Apr 10, 2024.
What are the highest and lowest recorded NADAC prices for ROFLUMILAST 250 MCG TABLET?
Since Apr 10, 2024, the NADAC for ROFLUMILAST 250 MCG TABLET has ranged from a low of $1.5913 (Jul 17, 2024) to a high of $3.0148 (Apr 10, 2024), with a median of $2.3360 per EA.
Are there cheaper alternatives to ROFLUMILAST 250 MCG TABLET?
5 NADAC-published products share the same active ingredient, strength, and dosage form as ROFLUMILAST 250 MCG TABLET, but none are currently priced below it.
Who manufactures ROFLUMILAST 250 MCG TABLET?
ROFLUMILAST 250 MCG TABLET (NDC 68382062431) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification